Contact Us / Sitemap / Directions / Patients and Visitors / Career Opportunities / Medical Staff
1-866-WINTHROP
pay your hospital bill pay your doctor's bill financial assistance policy
Winthrop University Hospital

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study

Summary

XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. It is an observational registry designed to evaluate XIENCE V EECSS safety and effectiveness in real world settings up to 1 year after implantation.

Description

Winthrop-University Hospital - Division of Cardiology is one of the participating site to enroll subjects receiving the XIENCE V EECSS during percutaneous coronary intervention. The objective is to determine clinical device and procedural success during commercial use in real world settings. Up to 8,000 subjects are consecutively enrolled at up to 275 sites across USA. Clinical follow-up is done at 14, 30, 180 days and 1 year as telephone contacts or office visits.

Inclusion/exclusion

Eligibility Criteria: - Subjects agree to participate in the study by signing the IRB approved informed consent form. - Subjects who receive the XIENCE V EECSS during percutaneous coronary intervention procedure.

Principal Investigator

Srihari Naidu, MD

Department

Division of Cardiology

Email

ssnaidu@winthrop.org

Other Contact

For more information please call Research Coordinator at 516-663-2929.
Contact Us / Sitemap / Directions / Career Opportunities / Financial Assistance / Policies
1-866-WINTHROP
subscribe
Winthrop-University Hospital
259 First Street | Mineola NY 11501 | 516-663-0333


This site provides information as a resource. It is not a substitute for professional medical advice.
Always consult a physician or healthcare provider for treatment and guidance toward good health.
Copyright © 2014 Winthrop-University Hospital. All rights reserved.
Web site by: Long Island Web Design
page-bottom